Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | LOXL2 | Q9Y4K0 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | LOX | P28300 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3040724 | 0.83 | NAAA (0.41) | NPC1RAB9ASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL8488280 | 0.79 | NAMPT (0.64) | HPGDALDH1A1NAMPTNPC1RAB9A | |
| SCHEMBL3029967 | 0.76 | HPGD (0.50) | HPGDALDH1A1NAMPTLOXL2NPC1 | |
| SCHEMBL1031249 | 0.75 | ALDH1A1 (0.46) | ALDH1A1TSHRL3MBTL1MAPT | |
| SCHEMBL1499143 | 0.75 | HDAC8 (0.44) | HPGDALDH1A1SMN1; SMN2TSHRHDAC6 | |
| SCHEMBL1416098 | 0.74 | HPGD (0.59) | HPGDALDH1A1LOXL2NPC1RAB9A | |
| SCHEMBL5592700 | 0.73 | HDAC6 (0.44) | ALDH1A1HDAC6 | |
| SCHEMBL7371434 | 0.73 | ROCK2 (0.55) | HPGDRAB9ASMN1; SMN2TSHRL3MBTL1 | |
| SCHEMBL17689058 | 0.73 | HPGD (0.56) | HPGDALDH1A1LOXL2NPC1RAB9A | |
| Lufironil SCHEMBL344625 | 0.73 | HPGD (0.56) | HPGDALDH1A1LOXL2TP53KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216791-A1 | PYRIDINYLQUINAZOLINAMINE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | ASTRAZENECA (SE) | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216791-A1 | PYRIDINYLQUINAZOLINAMINE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | BRAF, RAF1, ARAF | HPGD 1183/4885ALDH1A1 948/4885NAMPT 380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.